Compare prices and buy GHRP-2 from 9 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic hexapeptide, D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2 (C45H55N9O6, CAS 158861-67-7 for the free base), with the international nonproprietary name pralmorelin and the development code KP-102. It is an agonist at the ghrelin receptor, GHS-R1a, and is thought to release growth hormone mainly by acting through the hypothalamus. In healthy volunteers it also raised ACTH and cortisol, and in small studies it increased food intake. It is approved in Japan as GHRP Kaken 100, a single intravenous test for diagnosing growth hormone deficiency, but it is not FDA-approved, and FDA lists it in Category 2 of its 503B compounding policy for injectable and nasal use.
For research purposes only. Not medical advice.
GHRP-2 is a synthetic hexapeptide, D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2, with the international nonproprietary name pralmorelin and the development code KP-102. FDA's substance registry lists the free base under CAS 158861-67-7 with the formula C45H55N9O6. The dihydrochloride salt used in Japan's approved product has its own number, 158827-34-0, and weighs about 9 percent more.
In the late 1970s Cyril Bowers' laboratory at Tulane found that two analogs of the opioid peptide Met-enkephalin weakly released growth hormone from rat pituitary cells, then redesigned them into far more active peptides (Momany, Endocrinology, 1981). The group's 1984 hexapeptide became GHRP-6 (Bowers, Endocrinology, 1984). GHRP-2 came out of a collaboration between Bowers and Kaken Pharmaceutical, according to Japan's 2004 review of the drug, and shares GHRP-6's last four residues. Hexarelin is the other early analog.
The receptor came later. A Merck team cloned it from pituitary and hypothalamus and showed it was the target of these synthetic secretagogues (Howard, Science, 1996), and its natural ligand, the stomach hormone ghrelin, was identified in 1999 (Kojima, Nature).
GHRP-2 is an agonist at the ghrelin receptor, GHS-R1a, the target it shares with ipamorelin, GHRP-6 and hexarelin. Sermorelin, tesamorelin and CJC-1295 No DAC act at a different receptor, the GHRH receptor. Japan's label says it is thought to act mainly through the hypothalamus. In Kaken's rat studies the effect vanished without the pituitary and fell after median eminence lesions (Doi, Arzneimittel-Forschung, 2004).
The GHRH-plus-GHRP synergy result most often cited used GHRP-6, in 18 healthy men (Bowers, Journal of Clinical Endocrinology and Metabolism, 1990). For GHRP-2 itself, a Leuven study in 26 critically ill adults found that continuous infusion raised mean growth hormone four- to six-fold over placebo, and that adding GHRH doubled it again (Van den Berghe, same journal, 1997).
ClinicalTrials.gov holds no registration under GHRP-2, pralmorelin or KP-102 as of October 2026.
Japan approved GHRP-2 on October 22, 2004 as GHRP Kaken 100, a single intravenous injection for diagnosing growth hormone deficiency in adults and in children from age 4. Its label was last revised in July 2025. Japan's drug regulator reported in 2014 that it was approved and sold nowhere else.
No US application for pralmorelin appears in drugsfda as of October 2026. FDA granted pralmorelin hydrochloride an orphan drug designation in 2012 as a diagnostic agent for growth hormone deficiency. Its compounding status depends on pathway and route:
GHRP-2 is absent from the Category 2 page's withdrawn-nominations table and from every Pharmacy Compounding Advisory Committee agenda posted since 2016, and no FDA warning letter names it. The World Anti-Doping Agency's 2026 and 2027 lists name "GHRP-2 (pralmorelin)" under S2.2.4, prohibited at all times.
Only in Japan, and only as a diagnostic. Japan approved it on October 22, 2004 as GHRP Kaken 100, from Kaken Pharmaceutical, a single intravenous injection used to test for growth hormone deficiency in adults and in children aged 4 and older. It is not approved there as a treatment. In the United States, drugsfda holds no application for pralmorelin as of October 2026. FDA granted pralmorelin hydrochloride an orphan drug designation in 2012 as a diagnostic agent for growth hormone deficiency, but no product has been approved for that use, and Japan's drug regulator reported in 2014 that the drug was approved and sold in no other country.
In healthy volunteers it raised ACTH and cortisol, and in one study prolactin. In six healthy young adults in Turin, GHRP-2 raised prolactin, ACTH and cortisol, with the ACTH and cortisol rises about as large as those after corticotropin-releasing hormone (Arvat, Peptides, 1997). Japan's registration trials found ACTH rising with dose and cortisol rising within the reference range, and recorded no drug-related change in prolactin. In a 1998 swine study, GHRP-2 and GHRP-6 raised ACTH and cortisol while ipamorelin did not, the finding behind ipamorelin's description as the first selective growth hormone secretagogue.
All three are hexapeptides that act at the ghrelin receptor, GHS-R1a. GHRP-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, came first, from Cyril Bowers' laboratory in 1984. GHRP-2 replaces its first two residues with D-alanine and D-2-naphthylalanine and keeps the other four, while hexarelin adds a methyl group to GHRP-6's D-tryptophan. Compared directly in healthy young adults, GHRP-2 and hexarelin produced similar growth hormone, prolactin, ACTH and cortisol responses (Arvat, Peptides, 1997). The widely cited 1990 finding that a GHRP given with GHRH releases more growth hormone than either alone used GHRP-6.
It depends on the pathway and the route. Under section 503B, which covers outsourcing facilities, FDA placed GHRP-2 for injectable and nasal use in Category 2, its list of bulk drug substances that raise significant safety risks, on September 29, 2023. FDA cited immunogenicity, an unnatural amino acid and reports of serious adverse events, while stating that causality has not been established. Other routes sit in 503B Category 1, under evaluation. Under section 503A, GHRP-2 is in Category 3, nominated without adequate support. As of October 2026 it is not in the withdrawn-nominations table, and no Pharmacy Compounding Advisory Committee agenda posted since 2016 has named it.
Yes. Pralmorelin is the international nonproprietary name for GHRP-2, and KP-102 was Kaken Pharmaceutical's development code. FDA's substance registry lists pralmorelin, the free base, under CAS 158861-67-7 with the formula C45H55N9O6, and pralmorelin dihydrochloride, the salt in Japan's approved product, under CAS 158827-34-0. The salt weighs about 9 percent more per molecule, so the same milligram figure holds less peptide when it refers to the salt. Research listings use the name GHRP-2 and rarely state which form they contain.
GHRP-2 is sold by 9 research peptide vendors indexed on PeptideScouter, with 14 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
8 of the 9 indexed vendors currently have GHRP-2 in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Iron Protocol currently lists GHRP-2 at $2.34/mg, the lowest listed price across 9 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.99/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 9 vendors listing GHRP-2 publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $2.34/mg listed to $1.99/mg at Iron Protocol. Each vendor's code is shown beside its price in the table above.
GHRP-2 ranges from $2.34/mg to $7.80/mg across 14 listings from 9 research peptide vendors, normalized to USD per milligram and refreshed daily.
9 research peptide vendors currently list GHRP-2 on PeptideScouter, with 8 in stock right now. We track 14 listings across size and kit variants.
GHRP-2's CAS Registry Number is 158861-67-7.
